Glutamate ameliorates experimental vincristine neuropathy

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 1, 1996, Pages 410-415

  Boyle, Frances M ^a   Wheeler, Helen R ^a   Shenfield, Gillian M ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GAIT; INTRAPERITONEAL DRUG ADMINISTRATION; MOTOR NEUROPATHY; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; GAIT; GLUTAMIC ACID; MOTOR ACTIVITY; NEOPLASMS, EXPERIMENTAL; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; SENSORY THRESHOLDS; VINCRISTINE;

EID: 0030434257     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ALEXANDER, J. E., HUNT, D. F., LEE, M. K., SHABANOWITZ, J., MICHEL, H., BERLIN, S. C., MACDONALD, T. L., SUNDBERG, R. J., REBHUN, L. I. AND FRANKFURTER, A.: Characterization of posttranslational modifications in neuron-specific class III beta-tubulin by mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 88: 4685-4689, 1991.
2. APFEL, S. C., AREZZO, J. C., LEWIS, M. E. AND KESSLER, J. A.: The use of insulin-like growth factor I in the prevention of vincristine neuropathy in mice. Ann. N. Y. Acad. Sci. 692: 243-245, 1993.
3. APFEL, S. C., AREZZO, J. C., LIPSON, L. AND KESSLER, J. A.: Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. 31: 76-80, 1992.
4. APFEL, S. C., LIPTON, R. B., AREZZO, J. C. AND KESSLER, J. A.: Nerve growth factor prevents toxic neuropathy in mice. Ann. Neurol. 29: 87-90, 1991.
5. ARAKAWA, T. AND TIMASHEFF, S. N.: The mechanism of action of Na glutamate, lysine HCl, and piperazine-N,N′-bis(2-ethanesulfonic acid) in the stabilization of tubulin and microtubule formation. J. Biol. Chem. 259: 4979-4986, 1984.
6. BEECH, D., TSAN, R., POLLOCK, R. AND RADINSKY, R.: Growth factor enhancement of human soft tissue sarcoma cell lines by epidermal growth factor and insulin-like growth factor-1. Proc. Am. Assoc. Cancer Res. 36: 40, 1995.
7. BOYLE, F. M., DAVEY, R. A., BELL, D. R., WHEELER, H. R. AND FRIEDLANDER, M. L.: Glutamic acid does not inhibit in vitro cytotoxicity of Vinca alkaloids. Proc. Am. Assoc. Cancer Res. 33: 424, 1992.
8. CASEY, E. B., JELLIFE, A. M., LE QUESNE, P. M. AND MILLETT, Y. L.: Vincristine neuropathy: Clinical and electrophysiological observations. Brain 96: 69-86, 1973.
9. COYLE, P., ROFE, A. M., BOURGEOIS, C. S. AND CONYERS, R. A.: Biochemical manifestations of a rat mammary adenocarcinoma-producing cachexia: In vivo and in vitro studies. Immunol. Cell Biol. 68: 147-153, 1990.
10. CUTTS, J. H.: Effects of other agents on the biologic responses to vincaleukoblastine. Biochem. Pharmacol. 13: 421-431, 1964.
11. ESMAELI-AZAD, B., MCCARTY, J. H. AND FEINSTEIN, S. C.: Sense and antisense transfection analysis of tau function: Tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J. Cell Sci. 107: 869-879, 1994.
12. EUHUS, D. M., HUDD, C., LAREGINA, M. C. AND JOHNSON, F. E.: Tumor measurement in the nude mouse. J. Surg. Oncol. 31: 229-234, 1986.
13. GOTTSCHALK, P. G., DYCK, P. J. AND KIELY, J. M.: Vinca alkaloid neuropathy: Nerve biopsy studies in rats and in man. Neurology 18: 875-882, 1968.
14. HAMEL, E. AND LIN, C. M.: Glutamate-induced polymerization of tubulin: Characteristics of the reaction and application to the large-scale purification of tubulin. Arch. Biochem. Biophys. 209: 29-40, 1981.
15. JACKSON, D. V., JR., ROSENBAUM, D. L., CARLISLE, L. J., LONG, T. R., WELLS, H. B. AND SPURR, C. L.: Glutamic acid modification of vincristine toxicity. Cancer Biochem. Biophys. 7: 245-252, 1984.
16. JACKSON, D. V., JR., SETHI, V. S., SPURR, C. L. AND MCWHORTER, J. M.: Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res. 41: 1466-1468, 1981.
17. JACKSON, D. V., WELLS, H. B., ATKINS, J. N., ZEKAN, P. J., WHITE, D. R., RICHARDS, F., II, CRUZ, J. M. AND MUSS, H. B.: Amelioration of vincristine neurotoxicity by glutamic acid. Am. J. Med. 84: 1016-1022, 1988.
18. JOHNSON, I. S., WRIGHT, H. F., SVOBODA, G. S. AND VLANTIS, J.: Antitumor principles derived from Vinca Rosea Linn. I. Vincaleukoblastine and leurosine. Cancer Res. 20: 1016-1022, 1960.
19. JOURNEY, L. J., BURDMAN, J. AND WHALEY, A.: Electron microscopic study of spinal ganglia from vincristine-treated mice. J. Natl. Cancer Inst. 43: 603-619, 1969.
20. LIPTON, S. A. AND KATER, S. B.: Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. Trends Neurosci. 12: 265-270, 1989.
21. LIPTON, S. A. AND ROSENBERG, P. A.: Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330: 613-622, 1994.
22. MALGRANGE, B., DELREE, P., RIGO, J. M., BARON, H. AND MOONEN, G.: Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: Quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J. Neurosci. Methods 53: 111-122, 1994.
23. MOSKOWITZ, P. F., SMITH, R., PICKETT, J., FRANKFURTER, A. AND OBLINGER, M. M.: Expression of the class III beta-tubulin gene during axonal regeneration of rat dorsal root ganglion neurons. J. Neurosci. Res. 34: 129-134, 1993.
24. PEARCE, I. A., CAMBRAY-DEAKIN, M. A. AND BURGOYNE, R. D.: Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells. FEBS Lett. 223: 143-147, 1987.
25. PIROLLET, F., MARGOLIS, R. L. AND JOB, D.: Ca(2+)-calmodulin regulated effectors of microtubule stability in neuronal tissues. Biochim. Biophys. Acta 1160: 113-119, 1992.
26. PLUMMER, J. L., CMIELEWSKI, P. L., GOURLAY, G. K., OWEN, H. AND COUSINS, M. J.: Assessment of antinociceptive drug effects in the presence of impaired motor performance. J. Pharmacol. Methods 26: 79-87, 1991.
27. REBERT, C. S., PRYOR, G. T. AND FRICK, M. S.: Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. J. Appl. Toxicol. 4: 330-338, 1984.
28. ROWINSKY, E. K. AND DONEHOWER, R. C.: The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52: 35-84, 1991.
29. SANDLER, S. G., TOBIN, W. AND HENDERSON, E. S.: Vincristine-induced neuropathy: A clinical study of fifty leukemic patients. Neurology 19: 367-374, 1969.
30. SCHLAEPFER, W. W.: Vincristine-induced axonal alterations in rat peripheral nerve. J. Neuropathol. Exp. Neurol. 30: 488-505, 1971.
31. UY, Q. L., MOEN, T. H., JOHNS, R. J. AND OWENS, A. H., JR.: Vincristine neurotoxicity in rodents. Johns Hopkins Med. J. 121: 349-360, 1967.
32. VAN KOOTEN, B., VAN DIEMEN, H. A., GROENHOUT, K. M., HUIJGENS, P. C., OSSENKOPPELE, G. J., NAUTA, J. J. AND HEIMANS, J. J.: A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy. Arch. Neurol. 49: 1027-1031, 1992.
33. WISNIEWSKI, H., SHELANSKI, M. L. AND TERRY, R. D.: Effects of mitotic spindle inhibitors on neurotubules and neurofilaments in anterior horn cells. J. Cell Biol. 38: 224-229, 1968.